机器人辅助与电视辅助胸腔镜肺叶切除术随机对照试验短期结果
该单中心开放标签随机对照试验纳入320例非小细胞肺癌患者,比较机器人辅助与电视辅助胸腔镜肺叶切除术的围术期结果。两组住院时间和术后并发症发生率无显著差异,无围术期死亡;机器人组总胸腔引流量和住院费用更高,但淋巴结清扫数目更多。
要点
- 机器人辅助与电视辅助胸腔镜肺叶切除术的围术期结局相当且安全可行。
- 机器人组总胸腔引流量和住院费用显著高于电视辅助组。
- 机器人组淋巴结清扫数目、N1淋巴结数目及检查站数显著更多。
核心结论
- 机器人辅助和电视辅助胸腔镜肺叶切除术治疗非小细胞肺癌均安全可行。
- 机器人辅助实现相似的围术期结局,同时淋巴结清扫产出更高。
研究设计与样本
- 单中心、开放标签、前瞻性随机对照试验,2017年5月至2020年5月共纳入320例患者。
- 患者随机分配至机器人辅助组(n=157)和电视辅助胸腔镜组(n=163)。
主要发现
- 两组住院时间(P=0.76)和术后并发症发生率(P=0.45)无显著差异,两组均无围术期死亡。
- 机器人组总胸腔引流量为830 mL(IQR 550-1130 mL),电视辅助组为685 mL(IQR 367.5-1160 mL),P=0.007。
- 机器人组住院费用为12821美元(IQR 12145-13924美元),电视辅助组为8009美元(IQR 7014-9003美元),P<0.001。
- 机器人组淋巴结清扫数目为11枚(IQR 8-15),电视辅助组为10枚(IQR 8-13),P=0.02。
- 机器人组N1淋巴结数目为6枚(IQR 4-8),电视辅助组为5枚(IQR 3-7),P=0.005;检查站数为6站(IQR 5-7)对5站(IQR 4-6),P<0.001。
临床怎么用
- 在非小细胞肺癌肺叶切除术中,机器人辅助可获得与电视辅助胸腔镜相似的围术期安全性。
- 机器人辅助淋巴结清扫产出更高,但需权衡更高的引流量和住院费用。
- 长期疗效尚需进一步随访评估。
局限性
- 单中心研究。
- 开放标签设计。
- 长期疗效尚未报告,需进一步随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether RAL affects perioperative outcomes and long-term efficacy in NSCLC patients, compared with traditional VAL. SUMMARY OF BACKGROUND DATA: RAL is a promising treatment for NSCLC. However, its efficacy has not been fully evaluated. METHODS: A single-center, open-labeled prospective randomized clinical trial was launched in May 2017 to compare the efficacy of RAL and VAL. By May 2020, 320 patients were enrolled. The perioperative results of RAL and VAL were compared. RESULTS: The 320 enrolled patients were randomly assigned to the RAL group (n = 157) and the VAL group (n = 163). Perioperative outcomes were comparable between the 2 groups, including the length of hospital stay (P = 0.76) and the rate of postoperative complications (P = 0.45). No perioperative mortality occurred in either group. The total amount of chest tube drainage {830 mL [interquartile range (IQR), 550-1130 mL] vs 685 mL [IQR, 367.5-1160 mL], P = 0.007} and hospitalization costs [$12821 (IQR, $12145-$13924) vs $8009 (IQR, $7014-$9003), P < 0.001] were significantly higher in the RAL group. RAL group had a significantly higher number of LNs harvested [11 (IQR, 8-15) vs 10 (IQR, 8-13), P = 0.02], higher number of N1 LNs [6 (IQR, 4-8) vs 5 (IQR, 3-7), P = 0.005], and more LN stations examined [6 (IQR, 5-7) vs 5 (IQR, 4-6), P < 0.001]. CONCLUSIONS: Both RAL and VAL are safe and feasible for the treatment of NSCLC. RAL achieved similar perioperative outcomes, together with higher LN yield. Further follow-up investigations are required to evaluate the long-term efficacy of RAL. (ClinicalTrials.gov identifier: NCT03134534).
引用
- Jin R, Zheng Y, Yuan Y, et al. Robotic-assisted Versus Video-assisted Thoracoscopic Lobectomy: Short-term Results of a Randomized Clinical Trial (RVlob Trial). Ann Surg. 2022. PMID: 33938492. doi:10.1097/SLA.0000000000004922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。